ACM
REGN icon

Azimuth Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Azimuth Capital Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-1,000
Closed -$465K – 278
2015
Q3 		$465K Buy
+1,000
New +$537K 0.05% 230

Other funds holding REGN

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Azimuth Capital Management's REGN Position: Q4 2015 in Review

Azimuth Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q4 2015, closing a stake of 1,000 shares — an estimated $465K sold.

Azimuth Capital Management first reported a position in REGN in Q3 2015 and held it in 1 quarter. The position peaked at $465K in Q3 2015. 577 funds tracked by Wall St. Rank hold REGN as of Q4 2015.

  • Azimuth Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
  • Azimuth Capital Management sold 1,000 Regeneron Pharmaceuticals shares in Q4 2015, an estimated $465K.
  • Azimuth Capital Management first reported a position in Regeneron Pharmaceuticals in Q3 2015 and held it in 1 quarter.
  • Azimuth Capital Management's Regeneron Pharmaceuticals position peaked at $465K in Q3 2015.
  • 577 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2015.

Based on Azimuth Capital Management's 13F filing for Q4 2015, filed 9 Feb 2016.